Casellini, Carolina M.
- Assistant Professor, Internal Medicine
Publications
selected publications
-
2019Development and Validation of the Norfolk Quality of Life Fatigue Tool (QOL-F): A New Measure of Perception of Fatigue.. Journal of the American Medical Directors Association.Full Text via DOI: 10.1016/j.jamda.2019.10.021 PMID: 31859222
-
2018Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events. FRONTIERS IN NEUROSCIENCE.Full Text via DOI: 10.3389/fnins.2018.00591 PMID: 30210276
-
2017Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 102:4343-4410.Full Text via DOI: 10.1210/jc.2017-01922 PMID: 29126250
-
2016Bariatric Surgery Restores Cardiac and Sudomotor Autonomic C-Fiber Dysfunction towards Normal in Obese Subjects with Type 2 Diabetes. PLOS ONE. 11.Full Text via DOI: 10.1371/journal.pone.0154211 PMID: 27137224
-
2016Alternative Quantitative Tools in the Assessment of Diabetic Peripheral and Autonomic Neuropathy. CONTROVERSIES IN DIABETIC NEUROPATHY. 235-285.Full Text via DOI: 10.1016/bs.irn.2016.03.010 PMID: 27133153
-
2015Role of Peroxynitrite in the Development of Diabetic Peripheral Neuropathy. DIABETES CARE. e100-e101.Full Text via DOI: 10.2337/dc14-2918 PMID: 26106228
-
2015The new age of sudomotor function testing: a sensitive and specific biomarker for diagnosis, estimation of severity, monitoring progression, and regression in response to intervention. FRONTIERS IN ENDOCRINOLOGY.Full Text via DOI: 10.3389/fendo.2015.00094 PMID: 26124748
-
2013Diabetic Neuropathy. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA. 42:747-+.Full Text via DOI: 10.1016/j.ecl.2013.06.001 PMID: 24286949
-
2013Sudoscan, a Noninvasive Tool for Detecting Diabetic Small Fiber Neuropathy and Autonomic Dysfunction. DIABETES TECHNOLOGY & THERAPEUTICS. 15:948-953.Full Text via DOI: 10.1089/dia.2013.0129 PMID: 23889506
-
2013Contact Heat-Evoked Potential Stimulation for the Evaluation of Small Nerve Fiber Function. DIABETES TECHNOLOGY & THERAPEUTICS. 15:150-157.Full Text via DOI: 10.1089/dia.2012.0202 PMID: 23298343
-
2013Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. JOURNAL OF DIABETES INVESTIGATION. 4-18.Full Text via DOI: 10.1111/jdi.12042
-
2007A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. DIABETES CARE. 30:896-902.Full Text via DOI: 10.2337/dc06-1699 PMID: 17392551
-
2007Clinical Manifestations and Current Treatment Options for Diabetic Neuropathies. ENDOCRINE PRACTICE. 13:550-566.Full Text via DOI: 10.4158/ep.13.5.550
-
2006Pioglitazone treatment improves nitrosative stress in type 2 diabetes.. DIABETES CARE. 29:869-76.Full Text via DOI: 10.2337/diacare.29.04.06.dc05-0517 PMID: 16567830
-
2006Recent advances in the treatment of diabetic neuropathy. Current Opinion in Internal Medicine. 5:260-266.Full Text via DOI: 10.1097/01.med.0000216963.51751.be
-
2000
Research
research overview
- Dr. Casellini obtained her MD degree at the University of Salvador in Buenos Aires, Argentina and has specialized in Internal Medicine and Rheumatology. She joined Eastern Virginia Medical School in 2012 and is currently an Assistant Professor for the Department of Internal Medicine. She coordinates the Clinical Research Program at the Strelitz Diabetes Center - Endocrine & Metabolic Disorders, actively participating in the development, planning, management and conduction of a successful intra and extramurally funded program. She oversees multiple projects and has direct involvement in protocol development, study execution, analysis, and publication of results. Her main areas of expertise are on diabetes and its associated complications such as diabetic neuropathy, obesity and cardiovascular diseases. The Strelitz Diabetes Center has focused on identifying mechanisms of nerve damage that can ultimately lead to early detection, and to new therapeutic approaches. Their research has led to the discovery of treatments that have the potential to halt or reverse the progression of diabetic neuropathy and which are currently being investigated in Phase II clinical trials. Diabetes is also a major risk factor for cardiovascular disease. Currently funded research at the Diabetes Center is also contributing to further understand the mechanisms underlying the association between diabetes, obesity and cardiovascular disease. The Group has also developed and validated two clinical tools to evaluate the impact of diabetes and neuropathy on quality of life and fatigue. Dr. Casellini has been first or co-author of over 30 original research articles and book chapters, she is a member of the American Diabetes Association, and presents regularly at the national and international level in several scientific meetings including the American Diabetes Association, the American Association of Clinical Endocrinologists, the European Association for the Study of Diabetes, and the NEURODIAB Study Group.
projects
-
Current Project
- Hepatocyte Growth Factor (HGF) For Diabetic Neuropathy P.I. 2021 -
- Muscarinic Antagonists for Diabetic Neuropathy P.I. 2020 -
- Semaglutide for Cardiovascular Outcomes in Obese Subjects P.I. 2018 -
- Quality of Life (QOL) Tool to Examine Fatigue P.I. 2017 -
- Topiramate for Cryptogenic Sensory Peripheral Neuropathy (CSPN) P.I. 2018 - 2021
-
Grant
- A 12-Month, Adaptive, Phase 3, Double-Blind, Randomized, Placebo- Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants with Painful Diabetic Peripheral Neuropathy P.I. 2021 -
- A Randomized, Double-blind, Placebo-controlled, Parallel, 12-week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetes Mellitus Patients with Neuropathy P.I. 2020 -
- SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity P.I. 2018 -
- Utilizing a Quality of Life (QOL) Tool to Examine Fatigue in Cognitive and Physical Contexts P.I. 2017 -
- National Institutes of Health/National Institute of NeurTopiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN) P.I. 2018 - 2021
- The Effects of Liraglutide on SUDOMOTOR Function and Inflammation in Type 2 Diabetes P.I. - 2020
- Impact of Timed Bromocriptine-QR Therapy upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects P.I. - 2018
- Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy P.I. - 2018
- Development of a Quality of Life Tool Sensitive to Cognitive and Physical Measures of Fatigue P.I. - 2016
- Impact of Supervised vs. Home-Based Exercise Training on Gait, Balance, and Falls Risk in Type 2 Diabetes P.I. - 2016
- Peroxynitrite, Protein Nitration, and Peripheral Diabetic Neuropathy P.I. - 2015
-
Past Project
- The Effects of Liraglutide on SUDOMOTOR Function and Inflammation in Type 2 Diabetes P.I. - 2020
- Impact of Timed Bromocriptine-QR Therapy upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects P.I. - 2018
- Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy P.I. - 2018
- Development of a Quality of Life Tool Sensitive to Cognitive and Physical Measures of Fatigue - 2016
- Impact of Supervised vs. Home-Based Exercise Training on Gait, Balance, and Falls Risk in Type 2 Diabetes - 2016
- Peroxynitrite, Protein Nitration, and Peripheral Diabetic Neuropathy P.I. - 2015
Contact
full name
- Carolina M. Casellini